US6500948B1
(en)
|
1995-12-08 |
2002-12-31 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
|
DK0874830T3
(da)
*
|
1995-12-08 |
2003-04-22 |
Agouron Pharma |
Metalloproteinaseinhibitor, farmaceutisk præparat indeholdende denne og den farmaceutiske anvendelse samt en fremgangsmåde til fremstilling deraf
|
US6174915B1
(en)
|
1997-03-25 |
2001-01-16 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
US6008243A
(en)
*
|
1996-10-24 |
1999-12-28 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
|
US5985900A
(en)
*
|
1997-04-01 |
1999-11-16 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
WO1998050348A1
(en)
*
|
1997-05-09 |
1998-11-12 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
AUPO721997A0
(en)
*
|
1997-06-06 |
1997-07-03 |
Queensland Institute Of Medical Research, The |
Anticancer compounds
|
ATE217863T1
(de)
*
|
1997-08-08 |
2002-06-15 |
Pfizer Prod Inc |
Arylsulfonylaminohydroxamsäurederivate
|
PA8469301A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Procedimientos para la preparacion de acidos hidroxamicos.
|
EP0952148B1
(en)
*
|
1998-04-10 |
2004-05-12 |
Pfizer Products Inc. |
Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives
|
GT199900044A
(es)
*
|
1998-04-10 |
2000-09-14 |
|
Procedimientos para preparar haluros de fenoxifenilsulfonilo.
|
PA8469601A1
(es)
*
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Procedimiento para alquilar sulfonamidas impedidas estericamente
|
CN1178915C
(zh)
|
1999-01-27 |
2004-12-08 |
惠氏控股有限公司 |
含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途
|
US6277885B1
(en)
|
1999-01-27 |
2001-08-21 |
American Cyanamid Company |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
US6762178B2
(en)
|
1999-01-27 |
2004-07-13 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
US6225311B1
(en)
|
1999-01-27 |
2001-05-01 |
American Cyanamid Company |
Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
|
US6340691B1
(en)
|
1999-01-27 |
2002-01-22 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
|
US6200996B1
(en)
|
1999-01-27 |
2001-03-13 |
American Cyanamid Company |
Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
|
US6326516B1
(en)
|
1999-01-27 |
2001-12-04 |
American Cyanamid Company |
Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
|
US6313123B1
(en)
|
1999-01-27 |
2001-11-06 |
American Cyanamid Company |
Acetylenic sulfonamide thiol tace inhibitors
|
US6753337B2
(en)
|
1999-01-27 |
2004-06-22 |
Wyeth Holdings Corporation |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
US6946473B2
(en)
|
1999-01-27 |
2005-09-20 |
Wyeth Holdings Corporation |
Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
|
ATE245152T1
(de)
*
|
1999-03-31 |
2003-08-15 |
Pfizer Prod Inc |
Dioxocyclopentylhydroxamsäure
|
DE19920907A1
(de)
*
|
1999-05-06 |
2000-11-09 |
Basf Ag |
Verfahren zur Herstellung eines Cyclohexylglycin-Bausteins
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
SE0000382D0
(sv)
|
2000-02-07 |
2000-02-07 |
Astrazeneca Ab |
New process
|
US7141607B1
(en)
|
2000-03-10 |
2006-11-28 |
Insite Vision Incorporated |
Methods and compositions for treating and inhibiting retinal neovascularization
|
US6458822B2
(en)
|
2000-03-13 |
2002-10-01 |
Pfizer Inc. |
2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
|
DZ3494A1
(fr)
|
2001-01-05 |
2002-07-11 |
Pfizer |
Anticorps anti-recepteur du facteur de croissance i analogue a l'insuline
|
US6995171B2
(en)
|
2001-06-21 |
2006-02-07 |
Agouron Pharmaceuticals, Inc. |
Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
|
BR0213736A
(pt)
|
2001-11-01 |
2004-10-19 |
Wyeth Corp |
ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
CA2471814C
(en)
*
|
2001-12-27 |
2011-03-15 |
Sumitomo Pharmaceuticals Co., Ltd. |
Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
|
JP2005527511A
(ja)
|
2002-03-01 |
2005-09-15 |
ファイザー インコーポレイテッド |
抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法
|
EP1485131A1
(en)
*
|
2002-03-08 |
2004-12-15 |
Novartis AG |
Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer
|
ES2549159T3
(es)
|
2002-03-13 |
2015-10-23 |
Array Biopharma, Inc. |
Derivados de bencimidazol N3-alquilados como inhibidores de MEK
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
CN1747950A
(zh)
|
2002-12-19 |
2006-03-15 |
美国辉瑞有限公司 |
用于治疗眼病的作为蛋白激酶抑制剂的2-(1h-吲唑-6-基氨基)-苯甲酰胺化合物
|
WO2004056353A2
(en)
*
|
2002-12-20 |
2004-07-08 |
Novartis Ag |
Device and method for delivering mmp inhibitors
|
AU2003304456A1
(en)
|
2002-12-23 |
2005-03-16 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
|
AP2114A
(en)
|
2003-02-26 |
2010-03-04 |
Sugen Inc |
Aminoheteroaryl compounds as protein kinase inhibitors
|
EA008921B1
(ru)
*
|
2003-03-25 |
2007-08-31 |
Лаборатуар Фурнье С.А. |
Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
|
JP4638870B2
(ja)
|
2003-08-13 |
2011-02-23 |
ファイザー・プロダクツ・インク |
修飾ヒトigf−1r抗体
|
DE602004017479D1
(de)
|
2003-08-29 |
2008-12-11 |
Pfizer |
Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
DK1689233T3
(da)
|
2003-11-19 |
2012-10-15 |
Array Biopharma Inc |
Bicykliske inhibitorer af MEK
|
GEP20104906B
(en)
|
2004-08-26 |
2010-02-25 |
Pfizer |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
ES2333182T3
(es)
|
2005-05-18 |
2010-02-17 |
Array Biopharma, Inc. |
Derivados de 4-(fenilamino)-6-oxo-1,6-dihidropiridazina-3-carboxamida como inhibidores de mek para el tratamiento de enfermedades hiperproliferativas.
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
JP5055284B2
(ja)
|
2005-09-20 |
2012-10-24 |
オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー |
インシュリン様成長因子−1受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
|
TWI405756B
(zh)
|
2005-12-21 |
2013-08-21 |
Array Biopharma Inc |
新穎硫酸氫鹽
|
WO2007121269A2
(en)
|
2006-04-11 |
2007-10-25 |
Ardea Biosciences, Inc. |
N-aryl-n'alkyl sulfamides as mek inhibitors
|
CN101454004B
(zh)
|
2006-04-18 |
2013-12-04 |
阿迪亚生命科学公司 |
作为mek抑制剂的吡啶酮磺酰胺类和吡啶酮硫酰胺类
|
EP2121626A1
(en)
|
2006-12-15 |
2009-11-25 |
Pfizer Products Inc. |
Benzimidazole derivatives
|
BRPI0806898A2
(pt)
|
2007-01-19 |
2015-07-14 |
Ardea Biosciences Inc |
Inibidores de mek
|
DK2146779T3
(en)
|
2007-04-18 |
2016-11-28 |
Pfizer Prod Inc |
Sulfonylamid derivatives to treat abnormal cell growth.
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
CA2924436A1
(en)
|
2007-07-30 |
2009-02-05 |
Ardea Biosciences, Inc. |
Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use
|
PE20131210A1
(es)
|
2007-12-19 |
2013-10-31 |
Genentech Inc |
Derivados de 5-anilinoimidazopiridina como inhibidores de mek
|
CA2708176A1
(en)
|
2007-12-21 |
2009-07-02 |
Genentech, Inc. |
Azaindolizines and methods of use
|
MX2010007418A
(es)
|
2008-01-04 |
2010-11-12 |
Intellikine Inc |
Ciertas entidades quimicas, composiciones y metodos.
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
AU2009228093B2
(en)
|
2008-03-28 |
2014-08-07 |
Neurelis, Inc. |
Administration of benzodiazepine compositions
|
BRPI0915231A2
(pt)
|
2008-07-08 |
2018-06-12 |
Intellikine Inc |
compostos inibidores de quinase e métodos de uso
|
JP5836125B2
(ja)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
EP3100745B1
(en)
|
2009-02-05 |
2018-04-18 |
Immunogen, Inc. |
Novel benzodiazepine derivatives
|
EP2393814A1
(en)
|
2009-02-09 |
2011-12-14 |
SuperGen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
WO2010099137A2
(en)
|
2009-02-26 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the emt status of tumor cells in vivo
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
WO2010108652A1
(en)
|
2009-03-27 |
2010-09-30 |
Ardea Biosciences Inc. |
Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
|
CA2760791C
(en)
|
2009-05-07 |
2017-06-20 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
JP2013500991A
(ja)
|
2009-07-31 |
2013-01-10 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
mTOR阻害剤および血管新生阻害剤併用療法
|
GEP201706639B
(en)
|
2009-08-17 |
2017-03-27 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
JP2013503846A
(ja)
|
2009-09-01 |
2013-02-04 |
ファイザー・インク |
ベンズイミダゾール誘導体
|
WO2011047055A2
(en)
|
2009-10-13 |
2011-04-21 |
Allostem Therapeutics Llc |
Novel mek inhibitors, useful in the treatment of diseases
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
KR102012398B1
(ko)
|
2009-11-05 |
2019-08-20 |
리젠 파마슈티컬스 소시에떼 아노님 |
신규한 벤조피란 키나제 조절제
|
EP2533810B1
(en)
|
2010-02-10 |
2016-10-12 |
ImmunoGen, Inc. |
Cd20 antibodies and uses thereof
|
RS55487B1
(sr)
|
2010-02-12 |
2017-04-28 |
Pfizer |
Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
|
AU2011223643A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
US20110217309A1
(en)
|
2010-03-03 |
2011-09-08 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
DK2571878T3
(en)
|
2010-05-17 |
2019-02-11 |
Indian Incozen Therapeutics Pvt Ltd |
Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES
|
EP2571357B1
(en)
|
2010-05-21 |
2016-07-06 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
WO2011159835A1
(en)
|
2010-06-16 |
2011-12-22 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Antibodies to endoplasmin and their use
|
WO2012052948A1
(en)
|
2010-10-20 |
2012-04-26 |
Pfizer Inc. |
Pyridine- 2- derivatives as smoothened receptor modulators
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AR084824A1
(es)
|
2011-01-10 |
2013-06-26 |
Intellikine Inc |
Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
|
AU2012212075A1
(en)
|
2011-02-02 |
2013-07-18 |
Amgen Inc. |
Methods and compositons relating to inhibition of IGF-1R
|
MY183977A
(en)
|
2011-02-15 |
2021-03-17 |
Immunogen Inc |
Cytotoxic benzodiazepine derivatives
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
DK2699598T3
(en)
|
2011-04-19 |
2019-04-23 |
Pfizer |
COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
CN107337659A
(zh)
|
2011-05-04 |
2017-11-10 |
理森制药股份公司 |
作为蛋白激酶调节剂的新颖化合物
|
ES2683902T3
(es)
|
2011-06-14 |
2018-09-28 |
Hale Biopharma Ventures, Llc |
Administración de benzodiacepina
|
CN103946226A
(zh)
|
2011-07-19 |
2014-07-23 |
无限药品股份有限公司 |
杂环化合物及其应用
|
AU2012284088B2
(en)
|
2011-07-19 |
2015-10-08 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
ES2671748T3
(es)
|
2011-07-21 |
2018-06-08 |
Tolero Pharmaceuticals, Inc. |
Inhibidores heterocíclicos de proteína quinasas
|
WO2013032591A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
CN102408411B
(zh)
*
|
2011-09-19 |
2014-10-22 |
北京康辰药业股份有限公司 |
一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
CN103814030A
(zh)
|
2011-09-22 |
2014-05-21 |
辉瑞大药厂 |
吡咯并嘧啶及嘌呤衍生物
|
WO2013049332A1
(en)
|
2011-09-29 |
2013-04-04 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
EP2764025B1
(en)
|
2011-10-04 |
2017-11-29 |
IGEM Therapeutics Limited |
Ige-antibodies against hmw-maa
|
RU2014114015A
(ru)
|
2011-11-08 |
2015-12-20 |
Пфайзер Инк. |
Способы лечения воспалительных расстройств с использованием антител против m-csf
|
US9452215B2
(en)
|
2012-02-22 |
2016-09-27 |
The Regents Of The University Of Colorado |
Bourvadin derivatives and therapeutic uses thereof
|
EP2817004B1
(en)
|
2012-02-22 |
2018-04-11 |
The Regents of The University of Colorado, A Body Corporate |
Bouvardin derivatives and therapeutic uses thereof
|
SG11201406185WA
(en)
|
2012-03-30 |
2014-11-27 |
Rhizen Pharmaceuticals Sa |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP3505534A1
(en)
|
2012-06-08 |
2019-07-03 |
Sutro Biopharma, Inc. |
Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
|
ES2611788T3
(es)
|
2012-06-26 |
2017-05-10 |
Sutro Biopharma, Inc. |
Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
|
WO2014031566A1
(en)
|
2012-08-22 |
2014-02-27 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
BR112015004022B1
(pt)
|
2012-08-31 |
2023-04-25 |
Sutro Biopharma, Inc |
Aminoácidos modificados compreendendo um grupo azido
|
DK2909181T3
(da)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
NZ744567A
(en)
|
2012-11-01 |
2020-03-27 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
JP6494533B2
(ja)
|
2013-02-28 |
2019-04-03 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
|
WO2014134486A2
(en)
|
2013-02-28 |
2014-09-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
DK2970205T3
(da)
|
2013-03-14 |
2019-07-29 |
Tolero Pharmaceuticals Inc |
JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
TW201524952A
(zh)
|
2013-03-15 |
2015-07-01 |
Araxes Pharma Llc |
Kras g12c之共價抑制劑
|
BR112015029969A2
(pt)
|
2013-05-30 |
2017-07-25 |
Infinity Pharmaceuticals Inc |
tratamento de câncer usando moduladores de isoformas quinase pi3
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
WO2015051341A1
(en)
|
2013-10-03 |
2015-04-09 |
Araxes Pharma Llc |
Inhibitors of erk and methods of use
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JP6466924B2
(ja)
|
2013-10-04 |
2019-02-06 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
BR112016008016B8
(pt)
|
2013-10-10 |
2023-09-26 |
Araxes Pharma Llc |
Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditos compostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ou nras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dos ditos compostos
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
EP3137460B1
(en)
|
2014-04-30 |
2019-10-23 |
Pfizer Inc |
Cycloalkyl-linked diheterocycle derivatives
|
PE20170268A1
(es)
|
2014-06-19 |
2017-04-21 |
Ariad Pharma Inc |
Compuestos de heteroarilo para la inhibicion de cinasa
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
ES2848857T3
(es)
|
2014-07-31 |
2021-08-12 |
Us Gov Health & Human Services |
Anticuerpos monoclonales humanos contra EphA4 y su uso
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
US9862701B2
(en)
|
2014-09-25 |
2018-01-09 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
EP3280708B1
(en)
|
2015-04-10 |
2021-09-01 |
Araxes Pharma LLC |
Substituted quinazoline compounds and methods of use thereof
|
MX2017013275A
(es)
|
2015-04-15 |
2018-01-26 |
Araxes Pharma Llc |
Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos.
|
RU2717829C2
(ru)
|
2015-04-20 |
2020-03-26 |
Толеро Фармасьютикалз, Инк. |
Прогнозирование ответа на альвоцидиб с помощью анализа профиля митохондрий
|
WO2016178876A2
(en)
|
2015-05-01 |
2016-11-10 |
Cocrystal Pharma, Inc. |
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
ES2739749T3
(es)
|
2015-05-18 |
2020-02-03 |
Tolero Pharmaceuticals Inc |
Profármacos de alvocidib que tienen biodisponibilidad aumentada
|
TWI703150B
(zh)
|
2015-06-04 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
用於抑制menin及mll蛋白之交互作用的方法及組合物
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
WO2017024073A1
(en)
|
2015-08-03 |
2017-02-09 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
CA3005089A1
(en)
|
2015-11-16 |
2017-05-26 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
EA201891304A1
(ru)
|
2015-12-03 |
2019-01-31 |
Агиос Фармасьютикалс, Инк. |
ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
SG11201806419RA
(en)
|
2016-01-27 |
2018-08-30 |
Sutro Biopharma Inc |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
CN109640987B
(zh)
|
2016-03-16 |
2022-12-02 |
库拉肿瘤学公司 |
Menin-mll的桥联双环抑制剂及使用方法
|
CN114539284A
(zh)
|
2016-03-16 |
2022-05-27 |
库拉肿瘤学公司 |
经取代的menin-mll抑制剂及使用方法
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
WO2017197240A1
(en)
|
2016-05-12 |
2017-11-16 |
The Regents Of The University Of Michigan |
Ash1l inhibitors and methods of treatment therewith
|
US11118233B2
(en)
|
2016-05-18 |
2021-09-14 |
The University Of Chicago |
BTK mutation and ibrutinib resistance
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
AU2017321973A1
(en)
|
2016-09-02 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
MX2019007332A
(es)
|
2016-12-19 |
2019-11-18 |
Tolero Pharmaceuticals Inc |
Péptidos indicadores y métodos para caracterizar sensibilidad.
|
LT3558955T
(lt)
|
2016-12-22 |
2021-11-10 |
Amgen Inc. |
Benzizotiazolo, izotiazolo[3,4-b]piridazino ir ftalazino, pirido[2,3-d] piridazino ir pirido[2,3-d]pirimidino dariniai, kaip kras g12c inhibitoriai, skirti plaučių, kasos arba storosios žarnos vėžio gydymui
|
EP3573970A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
EP3573967A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
US11358959B2
(en)
|
2017-01-26 |
2022-06-14 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
CN110382483A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的n-杂环化合物及其使用方法
|
AU2018213718B2
(en)
|
2017-01-26 |
2022-08-25 |
Zlip Holding Limited |
CD47 antigen binding unit and uses thereof
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
EP3601249A4
(en)
|
2017-03-24 |
2020-12-16 |
Kura Oncology, Inc. |
METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
BR112019024674A2
(pt)
|
2017-05-25 |
2020-06-16 |
Araxes Pharma Llc |
Inibidores covalentes da kras
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
WO2019023316A1
(en)
|
2017-07-26 |
2019-01-31 |
Sutro Biopharma, Inc. |
METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
|
TWI731264B
(zh)
|
2017-09-08 |
2021-06-21 |
美商安進公司 |
Kras g12c抑制劑以及其使用方法
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
|
US20200353076A1
(en)
|
2017-09-18 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-folate receptor alpha antibody conjugates and their uses
|
EP3684361A4
(en)
|
2017-09-20 |
2021-09-08 |
Kura Oncology, Inc. |
MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
|
JP2021502388A
(ja)
|
2017-11-10 |
2021-01-28 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Ash1l阻害剤及びそれを用いた治療方法
|
JP7414282B2
(ja)
|
2017-12-07 |
2024-01-16 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Nsdファミリー阻害物質及びそれによる治療の方法
|
KR20210003780A
(ko)
|
2018-04-05 |
2021-01-12 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Axl 키나제 억제제 및 그의 용도
|
JP7266043B2
(ja)
|
2018-05-04 |
2023-04-27 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
MX2020011582A
(es)
|
2018-05-04 |
2020-11-24 |
Amgen Inc |
Inhibidores de kras g12c y metodos para su uso.
|
JP7361720B2
(ja)
|
2018-05-10 |
2023-10-16 |
アムジエン・インコーポレーテツド |
がんの治療のためのkras g12c阻害剤
|
EP3802535B1
(en)
|
2018-06-01 |
2022-12-14 |
Amgen, Inc |
Kras g12c inhibitors and methods of using the same
|
JP2021527064A
(ja)
|
2018-06-07 |
2021-10-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Prc1阻害剤及びそれを用いた治療方法
|
AU2019284472B2
(en)
|
2018-06-11 |
2024-05-30 |
Amgen Inc. |
KRAS G12C inhibitors for treating cancer
|
AU2019336588B2
(en)
|
2018-06-12 |
2022-07-28 |
Amgen Inc. |
KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
MX2021000977A
(es)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
|
US20210317127A1
(en)
|
2018-08-01 |
2021-10-14 |
Araxes Pharma Llc |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
US20210380595A1
(en)
|
2018-10-24 |
2021-12-09 |
Araxes Pharma Llc |
2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
EP3883565A1
(en)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CN113227092A
(zh)
|
2018-11-29 |
2021-08-06 |
亚瑞克西斯制药公司 |
化合物及其用于治疗癌症的使用方法
|
EP3890749A4
(en)
|
2018-12-04 |
2022-08-03 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT
|
WO2020132653A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
US11236069B2
(en)
|
2018-12-20 |
2022-02-01 |
Amgen Inc. |
KIF18A inhibitors
|
ES2953821T3
(es)
|
2018-12-20 |
2023-11-16 |
Amgen Inc |
Inhibidores de KIF18A
|
US20220056015A1
(en)
|
2018-12-20 |
2022-02-24 |
Amgen Inc. |
Kif18a inhibitors
|
KR20210146290A
(ko)
|
2019-02-12 |
2021-12-03 |
스미토모 다이니폰 파마 온콜로지, 인크. |
헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
|
EP3931195A1
(en)
|
2019-03-01 |
2022-01-05 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
AU2020232616A1
(en)
|
2019-03-01 |
2021-09-09 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
WO2020198077A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
EP3962951A1
(en)
|
2019-05-03 |
2022-03-09 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
US11236091B2
(en)
|
2019-05-21 |
2022-02-01 |
Amgen Inc. |
Solid state forms
|
CN114302878A
(zh)
|
2019-07-03 |
2022-04-08 |
大日本住友制药肿瘤公司 |
酪氨酸激酶非受体1(tnk1)抑制剂及其用途
|
JP2022542394A
(ja)
|
2019-08-02 |
2022-10-03 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
WO2021026099A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CN114391012A
(zh)
|
2019-08-02 |
2022-04-22 |
美国安进公司 |
作为kif18a抑制剂的吡啶衍生物
|
CA3146693A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
WO2021055728A1
(en)
|
2019-09-18 |
2021-03-25 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
WO2021067215A1
(en)
|
2019-09-30 |
2021-04-08 |
Agios Pharmaceuticals, Inc. |
Piperidine compounds as menin inhibitors
|
WO2021081212A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
CA3158793A1
(en)
|
2019-10-28 |
2021-05-06 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
US20230023023A1
(en)
|
2019-10-31 |
2023-01-26 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
CN115873020A
(zh)
|
2019-11-04 |
2023-03-31 |
锐新医药公司 |
Ras抑制剂
|
CN114867735A
(zh)
|
2019-11-04 |
2022-08-05 |
锐新医药公司 |
Ras抑制剂
|
EP4054719A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
KR20220100903A
(ko)
|
2019-11-08 |
2022-07-18 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로아릴 화합물 및 이의 용도
|
IL292315A
(en)
|
2019-11-14 |
2022-06-01 |
Amgen Inc |
Improved synthesis of a kras g12c inhibitory compound
|
AU2020383535A1
(en)
|
2019-11-14 |
2022-05-05 |
Amgen Inc. |
Improved synthesis of KRAS G12C inhibitor compound
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
TW202140011A
(zh)
|
2020-01-07 |
2021-11-01 |
美商銳新醫藥公司 |
Shp2抑制劑給藥和治療癌症的方法
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
TW202204334A
(zh)
|
2020-04-08 |
2022-02-01 |
美商阿吉歐斯製藥公司 |
Menin抑制劑及治療癌症之使用方法
|
WO2021204159A1
(en)
|
2020-04-08 |
2021-10-14 |
Agios Pharmaceuticals, Inc. |
Menin inhibitors and methods of use for treating cancer
|
WO2021215545A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
JP2023533982A
(ja)
|
2020-07-10 |
2023-08-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Gas41阻害剤及びその使用方法
|
US20230255972A1
(en)
|
2020-07-15 |
2023-08-17 |
Taiho Pharmaceutical Co., Ltd. |
Pyrimidine compound-containing combination to be used in tumor treatment
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
PE20231207A1
(es)
|
2020-09-15 |
2023-08-17 |
Revolution Medicines Inc |
Derivados indolicos como inhibidores de ras en el tratamiento del cancer
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
CN117396472A
(zh)
|
2020-12-22 |
2024-01-12 |
上海齐鲁锐格医药研发有限公司 |
Sos1抑制剂及其用途
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|
US11931420B2
(en)
|
2021-04-30 |
2024-03-19 |
Celgene Corporation |
Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
|
EP4334324A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
AU2022268962A1
(en)
|
2021-05-05 |
2023-12-14 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
AR125782A1
(es)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
EP4347041A1
(en)
|
2021-05-28 |
2024-04-10 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023056589A1
(en)
|
2021-10-08 |
2023-04-13 |
Servier Pharmaceuticals Llc |
Menin inhibitors and methods of use for treating cancer
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023211812A1
(en)
|
2022-04-25 |
2023-11-02 |
Nested Therapeutics, Inc. |
Heterocyclic derivatives as mitogen-activated protein kinase (mek) inhibitors
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
TW202408589A
(zh)
|
2022-06-30 |
2024-03-01 |
美商舒卓生物製藥公司 |
抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物,及製造及使用抗ror1抗體及抗體結合物之方法
|
WO2024010925A2
(en)
|
2022-07-08 |
2024-01-11 |
Nested Therapeutics, Inc. |
Mitogen-activated protein kinase (mek) inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|